The safety of MSC therapy over the past 15 years: a meta-analysis

Yang Wang1*†, Hanxiao Yi2† and Yancheng Song1*

Abstract
Background: Despite increasing clinical investigations emphasizing the safety of mesenchymal stem cell (MSC) therapy in different populations with different diseases, no article has recently reviewed the adverse events in all populations.
Aim: To evaluate the safety of MSC therapy in all populations receiving MSC therapy and explore the potential heterogeneities influencing the clinical application of MSCs.
Methods: The PubMed, Embase, Web of Science and Scopus databases were searched from onset until 1 March 2021.
Results: All adverse events are displayed as odds ratios (ORs) and 95% CIs (confidential intervals). In total, 62 randomized clinical trials were included that enrolled 3546 participants diagnosed with various diseases (approximately 20 types of diseases) treated with intravenous or local implantation versus placebo or no treatment. All studies were of high quality, and neither serious publication bias nor serious adverse events (such as death and infection) were discovered across the included studies. The pooled analysis demonstrated that MSC administration was closely associated with transient fever (OR, 3.65, 95% CI 2.05–6.49, \( p < 0.01 \)), administration site adverse events (OR, 1.98, 95% CI 1.01–3.87, \( p = 0.05 \)), constipation (OR, 2.45, 95% CI 1.01–5.97, \( p = 0.05 \)), fatigue (OR, 2.99, 95% CI 1.06–8.44, \( p = 0.04 \)) and sleeplessness (OR, 5.90, 95% CI 1.04–33.47, \( p = 0.05 \)). Interestingly, MSC administration trended towards lowering rather than boosting the incidence rate of arrhythmia (OR, 0.62, 95% CI 0.36–1.07, \( p = 0.09 \)).
Conclusions: Conclusively, MSC administration was safe in different populations compared with other placebo modalities.
Keywords: MSC therapy, Randomized clinical trials, All populations, Safety, Meta-analysis

Introduction
Mesenchymal stromal cells (MSCs), a class of highly heterogeneous cells that can be isolated from bone marrow, adipose tissue, the umbilical cord and the placenta, were primarily discovered in 1974 by Friedenstein [1]. Over the years, exogenous MSCs have amazingly been found to have therapeutic effects in many diseases (e.g. myocardial infarction, liver cirrhosis, limb ischaemia and spinal cord injury) [2–5].
Different from multipotent stem cells, the potency of MSCs is restricted, but MSCs can be induced into osteoblasts, chondrocytes and adipocytes in vitro. Universally, MSCs exert their favourable effects by immunomodulatory regulation and paracrine mechanisms [6, 7]. Clinically, MSCs have been applied in many refractory diseases, such as cerebral palsy [8], spinal cord injury [9] and systemic lupus erythematosus [10].

*Correspondence: wangyang5@mail2.sysu.edu.cn; songyancheng@21cn.com
†Yang Wang and Hanxiao Yi have contributed equally to this manuscript.
1 Department of Orthopedics, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, No. 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong Province, China
Full list of author information is available at the end of the article
However, MSCs easily gather together, forming the core of clots and leading to vascular disorders. Additionally, MSCs are tumourigenic as a result of their reproductive capacity and can potentially cause acute or chronic immunogenicity of the cells themselves as foreign matter [11–13]. A large number of studies, most of which have enrolled small samples, have investigated the safety of MSC transplantation, but no articles have reviewed these studies to characterize the adverse events closely associated with MSC administration over the past 9 years.

We performed this meta-analysis to identify all treatment-related adverse events concerning MSC administration and explore the safety of MSCs in clinical utilization.

Methods and materials

Search results

This meta-analysis was limited to published articles assessing the safety of MSC administration and was performed by searching the PubMed, EMBASE, Web of Science, Scopus and Cochrane Library databases (from inception to 1 March 2021). The search strategy was as follows: ((MSC [title/abstract]) OR (mesenchymal stem cell [title/abstract]) OR (Wharton’s jelly [title/abstract])) AND ((safety [title/abstract]) OR (side event [title/abstract]) OR (side effect [title/abstract]) OR (adverse event [title/abstract]) OR (adverse effect [title/abstract])). The reference lists of the included articles were also browsed to identify potential studies. To perform a comprehensive search, we did not limit the “study type”; retrospective studies were excluded during the study selection process. The detailed database search strategy is provided in Additional file 1.

Article selection

Primarily, duplicates of any articles were excluded. Two participants initially screened all titles and abstracts to preclude articles unrelated to our research objectives. Then, we carefully read the full manuscripts and selected the eligible manuscripts.

Eligibility criteria

The selection process strictly obeyed the PICOS (participants, interventions, comparison, outcome and study) principles, which are listed in Table 1.

Data extraction

Two skilled reviewers (YW and HXY) independently extracted data from all of the articles according to preset criteria. We retrieved 12 characteristic entries from the original articles, including author, year, study type, location, disease, cell type, administration method, study phase, language, dose, follow-up day and number of patients in each group. Conflicts were resolved in consultation with a third referee.

Quality assessment

Risk of bias in individual studies and across studies was performed using the Cochrane Collaboration’s tool for assessing the risk of bias.

Outcome definition

In total, we reported 17 adverse events that appeared during MSC therapy, of which 9 events (death, infection, diarrhoea, central nervous system disorders, arrhythmia, urticaria/dermatitis, vascular disorders, fever, administration site adverse events) were classified as major events, and 8 events (anaemia, constipation, metabolism disorders, fatigue, nausea, seizure, sleeplessness and vomiting) were classified as minor events. One event was considered a major event if it was reported by more than

Table 1 Inclusion and exclusion principles

| Principle   | Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|-------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Population  | Any populations including the healthy people and the diseased people               | NA                                                                                 |
| Intervention| Using MSC as treatment, regardless of the administration methods (e.g. local implantation and injection) and sources of MSC (e.g. from the adipose, bone marrow and gum) | Using NSC, ESC, olfactory neuron, Schwann cell, h-IPS and stem cell from body fluids (e.g. saliva, urine, serum and tears), etc. but MSC as interventions |
| Comparison  | Placebo treatment, nontreatment or basic treatment both utilized in the control and the intervention groups | Merely using traditional treatment (surgery and drug) in the control group but not in the intervention group |
| Outcome     | (1) Any side events associated with MSC treatment; (2) one side event reported by more than one study; (3) regardless of the efficacy of MSC therapy for any diseases | No side events reported |
| Study       | (1) RCT, (2) prospective controlled study                                         | (1) Case report (series); (2) single-arm study; (3) retrospective controlled study; (4) cross-controlled study; (5) study protocol |

ESC embryonic stem cell, MSC mesenchymal stromal cells, NSC neuronal stem cell, h-IPS human-induced pluripotent stem cell, NA not available
5 studies or was life-threatening as judged by our clinician; otherwise, it was classified as a minor event. Among these events, some events were not specifically clinical symptoms but referred to a series of correlated symptoms, such as central nervous system disorders, vascular disorders, infections, arrhythmias, administration site adverse events, and metabolism and nutrition disorders. These adverse events are redefined in Table 2. Other entries were retrieved from the original definitions.

Statistical analysis
All of the data were synthesized using R software, version 4.0.3 (University of Auckland, New Zealand). All of the results presented in this article are presented as odds ratios (ORs) with 95% CIs for outcomes. A random-effects model was used to analyse the data when heterogeneity was significant \((p < 0.05 \text{ or } I^2 > 50\%)\); otherwise, a fixed-effects model was used. Egger’s and Begg’s tests were utilized to analyse the publication bias of the included articles with R software, version 4.0.3 (meta-package). Subgroup analysis was also conducted to identify potential heterogeneous factors.

Results
The items of this meta-analysis were reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline (Additional file 2).

Article selection process
Approximately 2078 articles were identified after the initial search. A total of 1898 irrelevant articles were eliminated by browsing titles and abstracts, and 118 articles were excluded due to unexpected outcomes and interventions. Finally, 62 clinical trials, including 2 trials from reference lists, were included in the analysis despite the elimination of 2 systematic reviews (Fig. 1).

Baseline of included studies
The data were extracted from studies performed over the past 11 years. Only 2 studies were prospective, nonrandomized trials, and the rest were randomized, controlled trials (RCTs) ranging from study phase 1/2 to study phase 3. Asia was ranked first with the largest number of studies, followed by North America and Europe. The MSCs used in these studies were mainly isolated from bone marrow, adipose tissue and umbilical cords. The injection doses ranged from \(4 \times 10^7\) to \(1.2 \times 10^9\) cells. The follow-up length was from 6 months to 2 years (Table 3).

Pooled analysis of all studies
In total, 62 clinical trials containing populations with different characteristics were included in the analysis (Fig. 2A). We discovered that MSC administration was not closely related to major adverse events, such as vascular disorders \((1.17, 95\% \text{ CI } 0.52–2.62, p = 0.70)\), urticaria/dermatitis \((0.93, 95\% \text{ CI } 0.93–1.07, p = 0.70)\), central nervous system disorders \((1.13, 95\% \text{ CI } 0.61–2.12, p = 0.69)\), diarrhea \((0.90, 95\% \text{ CI } 0.49–1.63, p = 0.73)\), death \((0.99, 95\% \text{ CI } 0.66–1.49, p = 0.96)\) or infection \((1.03, 95\% \text{ CI } 0.70–1.53, p = 0.87)\). However, our analysis demonstrated that transient fever \((3.65, 95\% \text{ CI } 2.05–6.49)\) possibly occurred within 48 h if people received MSC administration. At the same time, MSC injections also potentially caused adverse events at the administration site \((1.98, 95\% \text{ CI } 1.01–3.87, p < 0.01)\). Populations tended to benefit from receiving MSC therapy since they tended to have a lower rate of arrhythmia \((0.62, 95\% \text{ CI } 0.36–1.07, p = 0.05)\).

Regarding minor adverse events, MSCs were potentially associated with sleeplessness \((5.90, 95\% \text{ CI } 1.04–33.47)\),

### Table 2. Outcome definition

| Side event                        | Definition                                                                 |
|-----------------------------------|---------------------------------------------------------------------------|
| Vascular disorders                | (1) Vascular thrombosis including venous and arterial thrombosis; (2) vasculitis |
| Arrhythmia                        | (1) PSVT; (2) VT; (3) atrial fibrillation; (4) ventricular fibrillation    |
| Central nervous disorders         | (1) dizzy; (2) headache                                                   |
| Diarrhoea                         | Noninfectious diarrhoea                                                  |
| Infection                         | (1) Noninjection site infection; (2) respiratory system infection; (3) urinary system infection; (4) biliary tract; (5) digestive tract and spontaneous peritonitis |
| Fever                             | Transient fever (low-grade, 37.3–38 °C) within 48 h                       |
| Administration site conditions    | (1) Injection site bleeding; (2) injection site swelling; (3) injection site pain; (4) injection site itch; (5) injection site infection |
| Anaemia                           | Defined by Hb < 110 g/L                                                   |
| Metabolism and nutrition disorders| Mainly refer to malnutrition                                             |

PSVT paroxysmal supraventricular tachycardia, VT ventricular tachycardia
constipation (2.45, 94% CI 1.01–5.97, \( p = 0.05 \)) and fatigue (2.99, 1.06–8.44, \( p = 0.05 \)). Other minor adverse events, including anaemia (1.25, 95% CI 0.39–4.07, \( p = 0.71 \)), metabolism and nutrition disorders (0.69, 95% CI 0.20–2.43, \( p = 0.56 \)), nausea (2.00, 95% CI 0.81–4.93, \( p = 0.13 \)), seizures (2.27, 94% CI 0.79–6.56, \( p = 0.13 \)) and vomiting (1.87, 95% CI 0.22–7.94, \( p = 0.40 \)), were nonsignificantly correlated with MSC treatment (Fig. 2B).

**Subgroup analysis of all studies**

Subsequently, we extracted potential factors, including administration (method), age, methodology (analysis) of the article, cell type, population (disease), gender proportion, location, study phase and publication date (year), influencing the major adverse events (Fig. 3A). We identified that the nonsignificance of death, infection and diarrhoea, which were not treatment-related adverse events of MSC therapy, were not altered in the slightest by any of the analysed factors. MSC therapy was demonstrated to be correlated with a lower incidence of arrhythmia in the population aged < 60 years old (\( p < 0.01 \)), those undergoing PP analysis (\( p = 0.01 \)) and those treated beyond 5 years (\( p < 0.01 \)). Despite the nonsignificant central nervous system disorders (head and dizziness) proved
by pooled analysis, AD-MSCs ($p<0.01$), placental MSCs ($p<0.01$) and uc-MSCs ($p<0.01$) more easily caused headache and dizziness. At the same time, a population with degenerative joint diseases ($p<0.01$) and digestive diseases ($p<0.01$) could potentially have headache and dizziness symptoms while receiving MSC implantation. Urticaria significantly occurred when the data were analysed exclusively by PP analysis ($p<0.01$). Regarding vascular disorders, Asian people tended to have vascular disorders ($p<0.01$) after MSC treatment. Administration site adverse events preferably occurred in studies with populations with age $<60$ years old ($p=0.02$), populations with heart-related diseases ($p=0.01$) and male proportions $>60$% ($p=0.08$), in study phase 1/2 ($p=0.01$), and within 5 years ($p=0.05$). Although transient fever was conspicuously associated with MSC treatment,
Fig. 3 (See legend on previous page.)
populations aged > 60 years old ($p = 0.86$), male proportion < 60% ($p = 0.7$), receiving local implantation ($p = 0.76$), being North American ($p = 0.82$) and phase 1 studies ($p = 0.15$) had a lower risk of transient fever over the period of MSC therapy.

In terms of minor adverse events, only five adverse events, namely anaemia, constipation, metabolism and nutrition disorders and nausea, were analysed (Fig. 3B). Similarly, the interactions between the 9 predicted factors and seldom reported adverse events were analysed. Contrary to the pooled analysis, neither constipation nor fatigue was a significant adverse event in these subgroup analyses. Similar to the pooled analysis, both metabolism and nutrition disorders and nausea were not impacted by these factors and were nonsignificant adverse events. Interestingly, we found that populations aged < 60 years old tended to have transient anaemia ($p = 0.07$) post-MSC treatment.

**Pooled analysis of high-quality studies**

After the elimination of low-quality articles (Kim 2018; Koh 2012; Lee 2017; Lin 2012; Oh 2018; Shi 2012; Sponer 2018; Wang 2006; Wang 2014; Wang 2016; Xie 2007; Zeng 2015; Xiao 2012; Skyler 2015), only seven major adverse events and one minor adverse event remained (Fig. 4). We found a close relationship between transient fever (3.08, 95% CI 1.67–1.48, $p = 0.01$) and MSC administration. Other adverse events, such as metabolism and nutrition disorders (0.49, 95% CI 0.11–2.10, $p = 0.33$), infection (1.05, 95% CI 0.59–1.61, $p = 0.83$), death (0.99, 95% CI 0.66–1.48, $p = 0.96$), arrhythmia (0.58, 95% CI 0.33–1.03, $p = 0.06$), central nervous system disorders (0.96, 95% CI 0.49–1.88, $p = 0.91$), vascular disorders (0.85, 95% CI 0.30–2.45, $p = 0.77$) and administration site adverse events (2.15, 95% CI 0.98–4.73, $p = 0.06$), were not significantly impacted by MSC administration.

**Subgroup analysis of high-quality studies**

We examined whether potential factors significantly influenced the terminal outcomes (7 major adverse events) reported by high-quality studies (Fig. 5). MSC administration does not directly lead to death, death, central nervous disorders (headache and dizziness) or vascular disorders. Populations aged < 60 years old ($p < 0.01$), those receiving BMSC injection ($p = 0.04$), those in study phase 3 ($p = 0.04$) and those treated beyond 5 years ($p < 0.01$) seemed to have a lower incidence of arrhythmia and benefit from MSC administration. Regarding transient fever, MSC administration did not trigger fever in populations aged > 60 years old ($p = 0.86$), those with male proportions < 60% ($p = 0.70$), Europeans ($p = 0.82$), phase 2 patients ($p = 0.15$), patients older than 5 years ($p = 0.11$) or patients receiving local implantation ($p = 0.76$).

**Sensitivity analysis**

Leave-one-out meta-analysis was performed for administration site adverse events, arrhythmia, death, dermatitis, diarrhoea, transient fever, infection, central nervous system disorders, vascular disorders, fatigue,
| Author     | Year | Study type | Location      | Disease                                | Cell          | Administration                      | Analysis | Study phrase | Language | Dose                          | Follow-up |
|------------|------|------------|---------------|----------------------------------------|---------------|-------------------------------------|----------|--------------|----------|-------------------------------|-----------|
| Emadedin   | 2018 | RCT        | Iran          | Knee osteoarthritis                    | BMSC          | Local implantation                  | PP 1/2   | English      | 40 x 10^6 cells               | 6 months |
| Gao        | 2013 | RCT        | China         | Acute myocardial infarction            | BMSC          | Intracoronary injection             | PP 3     | English      | (3.08 ± 0.52) x 10^6 cells    | 1 year   |
| Gupta      | 2013 | RCT        | India         | Critical limb ischemia                 | BMSC          | Local injection                     | ITT 1/2  | English      | 2 x 10^6 cells/kg             | 2 years  |
| Lee        | 2010 | RCT        | South Korea   | Ischemic stroke                        | BMSC          | Intravenous injection               | PP 3     | English      | 1 x 10^6 cells                 | 5 years  |
| Zollino    | 2018 | RCT        | Italy         | Chronic leg ulcers                     | BMSC          | Local injection                     | PP 2     | English      | NA                   | 24 weeks |
| Weiss      | 2013 | RCT        | USA           | Critical limb ischemia                 | BMSC          | Intravenous injection               | PP 3     | English      | 100 x 10^6 cells              | 2 years  |
| Xiao       | 2017 | RCT        | China         | Dilated cardiomyopathy                | BMSC          | Intracoronary injection             | PP 3     | English      | (4.9 ± 1.7) x 10^6 cells      | 1 year   |
| Hare       | 2009 | RCT        | USA           | Acute myocardial infarction            | BMSC          | Intravenous injection               | PP 3     | English      | 0.5, 1.6 and 5 x 10^6 cells/kg | 6 months |
| Huang      | 2018 | RCT        | China         | Cerebral palsy                         | uc-MSC        | Intravenous injection               | PP 3     | English      | 5 x 10^6 cells                | 2 years  |
| Centeno    | 2014 | RCT        | USA           | Knee osteoarthritis                    | BMSC          | Local implantation                  | PP 3     | English      | 75% BMSC, 12.5% PRP and 12.5% PBS | 2 years  |
| Fernández  | 2018 | RCT        | Spain         | Multiple sclerosis                     | AD-MSC        | Intravenous injection               | ITT 1/2  | English      | 1 x 10^6 cells/kg, 4 x 10^6 cells/kg | 1 year   |
| Vanginuss  | 2014 | RCT        | USA           | Partial medial meniscectomy           | BMSC          | Local implantation                  | PP 3     | English      | 50 x 10^6 cells               | 2 years  |
| Lin        | 2017 | RCT        | China         | Liver failure                          | BMSC          | Intravenous injection               | PP 3     | English      | 1.0–10 x 10^6 cells/kg        | 2 years  |
| Molendijk  | 2015 | RCT        | USA           | Crohn's disease                        | BMSC          | Local implantation                  | PP 3     | English      | 1–9 x 10^6 cells              | 2 years  |
| Tompkins   | 2017 | RCT        | USA           | Aging frailty                          | BMSC          | Intravenous injection               | PP 2     | English      | 100–200 x 10^6 cells           | 6 months |
| Li         | 2013 | RCT        | China         | Leg ischemia                           | BMSC          | Local implantation                  | PP 3     | English      | 1 x 10^6 cells/mL             | 6 months |
| Lee        | 2007 | RCT        | South Korea   | Multiple system atrophy                | BMSC          | Intravenous injection               | PP 3     | English      | 4 x 10^5 cells                | 1 year   |
| Jaillard   | 2020 | RCT        | France        | Ischemic stroke                        | BMSC          | Intravenous injection               | ITT 3    | English      | 100–300 x 10^6 cells           | 2 year   |
| Mathiasen  | 2019 | RCT        | Denmark       | Ischaemic heart failure                | BMSC          | Intramyocardial injection           | ITT 3    | English      | 0.2 mL                        | 1 year   |
| Bartunek   | 2016 | RCT        | USA           | Ischaemic heart failure                | BMSC          | Intramyocardial injection           | ITT 3    | English      | 24 x 10^6 cells               | 39 weeks |
| Bartunek   | 2013 | RCT        | Belgium       | Heart failure                          | BMSC          | Intramyocardial injection           | PP 3     | English      | 600–1200 x 10^6 cells          | 2 years  |
| Author       | Year | Study type | Location     | Disease                          | Cell                | Administration | Analysis | Study phrase | Language | Dose                        | Follow-up |
|--------------|------|------------|--------------|----------------------------------|---------------------|----------------|----------|--------------|----------|-----------------------------|-----------|
| Powell       | 2012 | RCT        | USA          | Critical limb ischemia           | BMSC                | Local implantation | PP       | 3            | English  | 0.5 ml                     | 1 year     |
| Olivera      | 2017 | RCT        | Brazil       | Pulmonary emphysema              | BMSC                | Intravenous injection | ITT      | 1            | English  | 10^6 cells                  | 3 months   |
| Sponer       | 2018 | Prospective study | Czech     | Femoral bone defects            | BMSC                | Local implantation | PP       | 3            | English  | (15±4.5) × 10^6 cells       | 1 year     |
| Wang         | 2016 | RCT        | China        | Knee osteoarthritis             | uc-MSC              | Local implantation | PP       | 3            | Chinese  | 2−3 × 10^3 cells            | 6 months   |
| Teraa        | 2015 | RCT        | The Netherlands | Limb ischemia                  | BMSC                | Local implantation | ITT      | 3            | English  | 144–500 × 10^6 cells        | 6 months   |
| Bhansali     | 2016 | RCT        | USA          | Diabetes mellitus               | BMSC                | Intravenous injection | PP       | 3            | English  | 1 × 10^6 cells/kg           | 1 year     |
| Panes        | 2016 | RCT        | Spain        | Crohn's disease                 | AD-MSC              | Intravenous injection | ITT      | 3            | English  | 120 × 10^6 cells            | 24 weeks   |
| Averyanov    | 2019 | RCT        | Russia       | Idiopathic pulmonary fibrosis   | BMSC                | Intravenous injection | PP       | 3            | English  | 2 × 10^6 cells              | 1 year     |
| Skyyler      | 2015 | RCT        | USA          | Type 2 diabetes                 | BMSC                | Intravenous injection | ITT      | 3            | English  | 0.3−2 × 10^6 cells/kg       | 1 year     |
| Shi          | 2010 | RCT        | China        | Chronic liver failure           | BMSC                | Intravenous injection | PP       | 3            | English  | 0.5 × 10^6 cells/kg         | 72 weeks   |
| Lublin       | 2014 | RCT        | USA          | Multiple sclerosis              | Placenta-Derived MSc | Intravenous injection | ITT      | 3            | English  | 600 × 10^6 cells            | 1 year     |
| Zhang        | 2011 | RCT        | China        | Liver cirrhosis                 | uc-MSC              | Intravenous injection | PP       | 3            | English  | 0.5 × 10^6 cells/kg         | 1 year     |
| Winkler      | 2018 | RCT        | Germany      | Hip arthroplasty                | Placenta-derived MSc | Local implantation   | ITT      | 3            | English  | 1.5−3.0 × 10^6 cells        | 2 years    |
| Kim          | 2018 | RCT        | South Korea  | Myocardial infarction           | BMSC                | Intracoronary injection | PP       | 3            | English  | (72.0±0.9) × 10^7 cells     | 1 year     |
| Tan          | 2012 | RCT        | China        | Kidney transplants              | BMSC                | Intravenous injection | PP       | 3            | English  | 1−2 × 10^6/kg               | 1 year     |
| Hauzeur      | 2017 | RCT        | Belgium      | Osteonecrosis                   | BMSC                | Local implantation   | PP       | 3            | English  | 50 ml                      | 2 years    |
| Noriega      | 2017 | RCT        | Spain        | Intervertebral disc regeneration | BMSC                | Local implantation   | PP       | 3            | English  | 25 × 10^6 cells             | 1 year     |
| Gao          | 2015 | RCT        | China        | Myocardial infarction           | uc-MSC              | Intracoronary injection | PP       | 3            | English  | 6 × 10^6 cells              | 18 months  |
| Ascheim      | 2014 | RCT        | USA          | Left ventricular assist device patients | BMSC | Intramyocardial injection | PP       | 3            | English  | 25 × 10^6 cells             | 1 year     |
| Koh          | 2012 | RCT        | South Korea  | Knee osteoarthritis             | BMSC                | Local implantation   | PP       | 3            | English  | 1.89 × 10^6 cells           | 1 year     |
| Berry        | 2019 | RCT        | USA          | Amyotrophic lateral sclerosis   | BMSC                | Local implantation   | PP       | 2            | English  | 125 × 10^6 cells            | 6 months   |
| Author         | Year | Study type | Location        | Disease                                      | Cell                          | Administration                      | Analysis | Study phrase | Language | Dose                        | Follow-up |
|---------------|------|------------|-----------------|----------------------------------------------|-------------------------------|-------------------------------------|----------|--------------|----------|-----------------------------|-----------|
| Chullikana    | 2014 | RCT        | India           | Acute myocardial infarction                  | BMSC                          | Intracoronary injection             | PP 1/2   | English      | 6.0 × 10⁷ cells             | 2 years       |
| Oh            | 2018 | RCT        | Republic of Korea | Amyotrophic lateral sclerosis               | BMSC                          | Intrathecal injections              | ITT 3    | English      | 1 × 10⁶ cells/kg            | 6 months      |
| Hess          | 2017 | RCT        | USA             | Acute ischaemic stroke                      | BMSC                          | Intracerebral injection             | ITT 2    | English      | 1200 × 10⁶ cells            | 3 months      |
| Bartolucci    | 2017 | RCT        | Chile           | Heart failure                                | uc-MSC                        | Intravenous injection               | PP 1/2   | English      | 1 × 10⁶ cells/kg            | 1 year        |
| Wang          | 2017 | RCT        | Australia       | Anterior cruciate ligament reconstruction patients | BMSC                          | local implantation                  | ITT 3    | English      | 150 × 10⁶ cells             | 104 weeks     |
| Wang          | 2014 | RCT        | China           | Lyocardial infarction                        | BMSC                          | Intracoronary injection             | PP 3     | English      | 1 × 10⁶ cells/ml            | 1 month       |
| Gu            | 2020 | RCT        | China           | Cerebral palsy                               | uc-MSC                        | Intravenous injection               | PP 3     | English      | 4.5–5.5 × 10⁶ cells         | 1 year        |
| Zhang         | 2016 | RCT        | China           | Liver transplantation                        | uc-MSC                        | Intravenous infusion                | PP 3     | English      | 1.0 × 10⁶ cells/kg          | 2 years       |
| Suk           | 2016 | RCT        | South Korea     | Alcoholic cirrhosis                          | BMSC                          | Hepatic arterial injection          | PP 2     | English      | 5 × 10⁶ cells               | 1 year        |
| Zheng         | 2014 | RCT        | China           | Acute respiratory distress syndrome          | AD-MSC                        | Intravenous infusion                | PP 3     | English      | 1 × 10⁶ cells/kg            | 4 weeks       |
| Matas         | 2019 | RCT        | Chile           | Knee Osteoarthritis                          | AD-MSC                        | Local implantation                  | PP 1/2   | English      | 2 × 10⁶ cells               | 1 year        |
| Wang          | 2006 | RCT        | China           | Dilated cardiomyopathy                       | BMSC                          | Intracoronary injection             | ITT 3    | Chinese      | 8 × 10⁶ cells               | 6 months      |
| Lin           | 2012 | RCT        | China           | Liver fibrosis                               | uc-MSC                        | Intravenous infusion                | ITT 3    | Chinese      | 0.5–1 × 10⁶ cells/kg        | 48 weeks      |
| Xie           | 2007 | RCT        | China           | Spinal cord injury                           | BMSC                          | Intrathecal injection               | ITT 3    | Chinese      | 20.56–58.87 × 10⁶ cells     | 3 months      |
| Xiao          | 2012 | RCT        | China           | Myocardial infarction                        | BMSC                          | Intracoronary injection             | ITT 3    | Chinese      | 1–10 × 10⁶ cells            | 3 months      |
| Erpicum       | 2018 | RCT        | Belgium         | Kidney transplantation                       | BMSC                          | Intravenous injection               | PP 1/2   | English      | 2 × 10⁶ cells/kg            | 1 year        |
| Shadmafar     | 2017 | Prospective study | China       | Liver fibrosis                               | uc-MSC                        | Hepatic artery injection            | ITT 3    | English      | (42 ± 4) × 10⁶ cells         | 1 year        |
| Zeng          | 2015 | RCT        | Iran            | Rheumatoid arthritis                         | BMSC                          | Local implantation                  | PP 1/2   | Chinese      | 6.0–7.0 × 10⁷ cells/kg      | 52 weeks      |
| Ning          | 2008 | RCT        | China           | Hematologic malignancy                       | BMSC                          | Intravenous injection               | NA       | NA           | 1.0–2.0 × 10⁶ cells/kg      | 3 years       |
| José          | 2020 | RCT        | Spain           | Knee osteoarthritis                          | BMSC                          | Local implantation                  | ITT 2    | English      | 100 × 10⁶ cells             | 1 year        |

uc-MSC human umbilical cord mesenchymal stromal cell, BMSC bone marrow-derived human umbilical cord mesenchymal stromal cell, AD-MSC adipose-derived human umbilical cord mesenchymal stromal cell, PP per-protocol, ITT intention to treat, RCT randomized clinical trial, COPD chronic obstructive pulmonary disease
metabolism and nutrition disorders, anaemia, constipation and nausea from all studies (Additional files 3–16) and for administration site adverse events, arrhythmia, death, transient fever, infection, central nervous system disorders and vascular disorders from high-quality studies (Additional file 17–23).

Publication bias and article quality
We assessed the article quality using the Cochrane Collaboration’s tool for assessing the risk of bias (Fig. 6). We concluded that most study designs were suitable and of high quality. Only 14 studies were considered low quality because they had more than two entries marked as high risk and fewer than four entries evaluated as low risk. There were performance bias, selection bias, detection bias and attrition bias potentially lowering the integral quality of the included studies. Furthermore, we tested the publication bias for administration site adverse events, arrhythmia, death, dermatitis, diarrhoea, transient fever, infection, central nervous system disorders and vascular disorders (Additional files 24–32) from all of the studies. Publication bias for administration site adverse events, arrhythmia, death, fever, infection, central nervous system disorders and vascular disorders (Additional files 33–39) from high-quality studies was also conducted.

Discussion
Summary of evidence
The association between adverse events and MSC administration was first reported by Lalu [14], and the associations of MSC administration with infusional toxicity, organ system complications, infection and death were not explored due to limited clinical research. However, aside from the adverse events above, which were analysed in this meta-analysis, more adverse events have been described in recent trials with the expansion of the population. In addition to transient fever, which is the most frequently reported event by researchers, other adverse events, such as constipation, fatigue, administration site adverse events and sleeplessness, can also be induced by MSC administration. For arrhythmia, MSCs seemed to benefit patients with cardiac diseases.

We were unable to detect conspicuous associations between MSC administration and the remaining adverse events (vascular disorders, urticaria/dermatitis, dizziness/headache, diarrhoea, infection, death, anaemia, metabolism and nutrition disorders, nausea, seizure and vomiting), nor was there direct proof suggesting that MSC administration was tumourigenic. To date, malignancy of MSCs has been reported only by Ning [15] despite their potential tumourigenesis.

After the elimination of the low-quality studies, eight adverse events were analysed: including metabolism and nutrition disorders, infection, fever, death, arrhythmia, dizziness/headache, vascular disorders and administration site effects. Among these adverse events, transient fever was exclusively associated with MSC administration. Arrhythmia and administration site adverse events tended to be significant after MSC administration. Other adverse events had no relevance to MSC administration.

Furthermore, we analysed each adverse event in various subpopulations to identify how adverse events were determined. We discovered that age, sex proportion, location, year, analysis, disease, study phase, cell type and administration method were the main factors impacting the final adverse events. Considering the definite adverse event of fever as an example, the elderly were not impacted by MSC administration, perhaps because of blunt reactions of the organism to acute inflammation triggered by MSCs [16]. Women more easily suffer from transient fever, and the oestrogen level is under serious doubt [17]. The population in North America underwent transient fever less often than other regional populations, which could suggest racial discrepancies in MSC administration.

Strengths and weaknesses
This meta-analysis removed studies with low-grade evidence (retrospective studies, single-arm studies and case studies) and included 62 prospective studies. All of the results suggested strong associations of MSC administration with transient fever and administration site adverse events. Moreover, more adverse events that were not reported before (e.g. anaemia, constipation and vomiting) are gradually being discovered [18–20]. Theoretically, the adverse events of MSC administration should be under stringent surveillance in cases of the occurrence of other adverse events that were not reported earlier, along with the expansion of clinical trials. We also noted that the longest follow-up was 5 years, which might be a shorter time considering that we are using cell products. We should be cautious that longer-term events in the future might be impeded.

Our research has limitations. First, we synthesized the data across heterogeneous disease states. Despite subgroup analysis of disease, it was difficult to distinguish whether one adverse event was specifically disease-related owing to the limited number of studies. Second, some studies presented their data in the form of abstracts prior to formal publication, which might have imposed an unknown effect on the interpretation of the outcomes. These data are difficult for us to obtain because many ongoing trials are in the middle stages and the investigators not want to release these data. Third, several adverse
events were merely comprehensive conceptions rather than specific clinical symptoms, and we contend that it was important to record these obscure descriptions (e.g., metabolism and nutrition disorders and gastrointestinal dysfunction). Fourth, we were not informed whether the cell dose was closely associated with these adverse events as a result of the lack of dose-dependent trials. If possible, a Bayesian network meta-analysis should be conducted to investigate this point further. Finally, tumourigenesis, which theoretically exists in MSC therapy, has rarely been reported by researchers. This interesting point should draw our attention.

The most clear adverse event discovered by this research was fever, which was presumably caused by the immunoregulatory actions of MSCs, and patients should be informed of this adverse event. Moreover, the security of mass production and uniform quality of MSCs should be resolved if we want the large-scale application of MSCs. Moreover, if we can find a better substitute (a noncell agent) for MSCs, such as MSC-derived microvesicles, which potentially share equal treatment effects as MSCs, the adverse events reported by our research might be of less concern.

Conclusions
We summarized all adverse events potentially related to the application of MSCs, and no serious safety events other than transient fever, administration site adverse events, sleeplessness and constipation were discovered. Many population characteristics, including age, analysis, cell type, disease, sex, location, study phase, year and
Fig. 6 Quality assessment of included articles. A Quality assessment of each article. B Pooled result of quality assessment
administration method, possibly impacted the occurrence of one adverse event. The safety of MSC administration should be assured under sustained observation despite the innovative therapy appearing safe.

Abbreviations
OR: Odds ratio; CI: Confidential intervals; RCTs: Randomized clinical trials; MSCs: Mesenchymal stromal cells; PICOS: Participants, interventions, comparison, outcome and study; NO.: Number; PRISMA: Systematic review and meta-analysis; pp: Per-protocol; ESC: Embryonic stem cell; NSC: Neuronal stem cell; h-IPS: Human-induced pluripotent stem cell; PSVT: Paroxysmal supraventricular tachycardia; VT: Ventricular tachycardia; COPD: Chronic obstructive pulmonary disease; BMSC: Bone marrow-derived human umbilical cord mesenchymal stromal cell; AD-MSC: Adipose-derived human umbilical cord mesenchymal stromal cell; NA: Not available.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13287-021-02609-x.

Acknowledgements
Not applicable.

Authors’ contributions
YCS and YW participated in conceptualization and supervision and wrote the original draft; YW and HXY had contributed to methodology, investigation and formal analysis; YW was involved in software; YCS took part in writing, reviewing and editing; and HXY acquired the funding. All of the authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
No conflicts of interest are declared.

Consent to participate
Not applicable.

Author details
1Department of Orthopedics, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, No. 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong Province, China.
2Department of Radiotherapy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. No. 600 Tianhe Road, Tianhe District, Guangzhou, Guangdong Province, China.

Received: 2 June 2021 Accepted: 25 September 2021
Published online: 18 October 2021
References
1. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17(4):331–40.

2. Lalu MM, Mazzarello S, Zeppigni J, Dong YYR, Montroy J, McIntyre L, et al. Safety and efficacy of adult stem cell therapy for acute myocardial infarction and ischemic heart failure (safecell heart): a systematic review and meta-analysis. Stem Cells Transl Med. 2018;7(12):857–66.

3. Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 2015;30(5):580–9.

4. Jin MC, Medress ZA, Azad TD, Ren G. Mesenchymal stem cells: from regeneration to cancer. Pharmacol Ther. 2019;200:42–54.

5. Le Blanc K, Davies LC. Mesenchymal stromal cells and the innate immune response. Immunol Lett. 2015;168(2):140–6.

6. Lalu MM, McIntyre L, Pugliese C, Ferguson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559.

7. Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis: a randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant. 2018;27(2):325–34.

8. Zollino I, Campioni D, Sibilla MG, Tessari M, Malagoni AM, Zamboni P. A phase II randomized clinical trial for the treatment of recalcitrant chronic leg ulcers using centrifuged adipose tissue containing progenitor cells. Cytotherapy. 2019;21(2):200–11.

9. Coelho LCM, Cruz JV, Maba IK, Zampronio AR. Fever induced by zymosan A and polyinosinic-polycytidylic acid in female rats: influence of sex hormones and the participation of endothelin-1. Inflammation. 2021;44(1):321–33.

10. Neves J, Sousa-Victor P. Regulation of inflammation as an anti-aging intervention. FEBS J. 2020;287(1):43–52.

11. Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant. 2018;27(2):325–34.

12. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22(3):593–9.

13. Cortez-Toledo E, Rose M, Agu E, Dahlenburg H, Yao W, Nolta JA, et al. Enhancing retention of human bone marrow mesenchymal stem cells with prosurvival factors promotes angiogenesis in a mouse model of limb ischemia. Stem Cells Dev. 2019;28(2):114–9.

14. Liu F, Qiu H, Xue M, Zhang S, Zhang X, Xu J, et al. MSC-secreted TGF-β regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt/FoxO1 pathway. Stem Cell Res Ther. 2019;10(1):345.

15. Simon-Martinez C, Mailleux L, Ortibus E, Fehrenbach A, Sgandurra G, Cioni G, et al. Combining constraint-induced movement therapy and action-observation training in children with unilateral cerebral palsy: a randomized controlled trial. BMC Pediatr. 2018;18(1):250.

16. Jin MC, Medress ZA, Azad TD, Ren G. Mesenchymal stem cells: from regeneration to cancer. Pharmacol Ther. 2019;200:42–54.

17. Le Blanc K, Davies LC. Mesenchymal stromal cells and the innate immune response. Immunol Lett. 2015;168(2):140–6.

18. Lalu MM, McIntyre L, Pugliese C, Ferguson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559.

19. Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis: a randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant. 2018;27(2):325–34.

20. Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2015;149(4):918–27.e6.